| Overview |
| Panacor has successfully built up its product portfolio by continuously acquiring state of the art technologies and collaborations with renowned research institutions worldwide. The lead product Nephoxil®is in Phase III market approval development and there are two other patented products in the development pipeline targeting renal disease patients. Two additional candidates under evaluation are in the pipeline providing new generation therapies for premenstrual syndrome and cancer patients. |
|
|
